Lupin receives approval from U.S. FDA for Sevelamer Carbonate for Oral Suspension

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Sevelamer Carbonate for Oral Suspension, 0.8 g and 2.4 g packets to market a generic equivalent of Renvela® for Oral Suspension, 0.8 g and 2.4 g Packets of Genzyme. This product will be manufactured at Lupin's Goa facility in India.

Sevelamer Carbonate for Oral Suspension (RLD: Renvela® for Oral Suspension) had estimated annual sales of USD 51.7 million in the U.S. (IQVIA MAT September 2021).

Shares of Lupin Limited was last trading in BSE at Rs. 897.15 as compared to the previous close of Rs. 912.25. The total number of shares traded during the day was 48499 in over 2637 trades.

The stock hit an intraday high of Rs. 925.00 and intraday low of 895.50. The net turnover during the day was Rs. 44030975.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Approval USFDA ANDA SevelamerCarbonate